Advertisement

Acta Diabetologica

, Volume 30, Issue 3, pp 149–153 | Cite as

Acute renal effects of angiotensin converting enzyme inhibition in microalbuminuric type 1 diabetic patients

  • K. W. Hansen
  • M. Mau Pedersen
  • J. S. Christiansen
  • C. E. Mogensen
Originals

Abstract

The renal effects of intravenous injection of 40 mg enalapril were investigated in 16 normotensive microalbuminuric type 1 (insulin-dependent) diabetic patients. After enalapril the following changes were observed: fractional albumin clearance (Θ Alb) decreased from 9.9 (3.0–23.8) to 8.2 (2.0–18.3)×10−6 (2P<0.01); filtration fraction (FF) decreased from 0.260 (0.225–0.312) to 0.253 (0.190–0.297) (2P<0.01); renal plasma flow (RPF) increased from 565 (411–690) to 623 (449–785) (2P<0.01); and glomerular filtration rate (GFR) remained stable at 149 (128–181) versus 150 (124–185) ml · min−1 (NS). These values were unchanged after placebo (n=8), except for RFP which decreased from 606 (401–701) to 559 (381–677) ml · min−1 (2P<0.05) and GFR which was reduced from 148 (111–173) to 138 (111–167) (2P<0.05). A reduction in mean blood pressure from 94 (87–103) to 89 (79–101) mmHg (2P<0.05) was found in the enalapril group and a minor reduction in the placebo group from 97 (83–106) to 96 (81–104) mmHg (2P<0.05) was also noted. The relative changes in systolic blood pressure in the enalapril group correlated with changes in Θ Alb (Spearman'sr=0.66, 2P<0.02) and FF (r=0.53, 2P<0.05). Acute inhibition of angiotensin converting enzyme does not reduce the pathological hyperfiltration in these patients and a reduction in Θ Alb and FF can not be dissociated from the reduction in blood pressure.

Key words

Angiotensin converting enzyme inhibition Microalbuminuria Renal haemodynamics Type 1 diabetes 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Hansen KW, Mau Pedersen M, Christensen CK, Schmitz A, Christiansen JS, Mogensen CE, Normoalbuminuria ensures no reduction of renal function in type 1 (insulin-dependent) diabetic patients. J Intern Med 232:161–167, 1992Google Scholar
  2. 2.
    Viberti GC, Jarrett RJ, Mahmud U, Hill RD, Argyropoulos A, Keen H, Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet I:1430–1432, 1982Google Scholar
  3. 3.
    Parving H-H, Oxenbøll B, Svendsen PA, Christiansen JS, Andersen AR, Early detection of patients at risk of developing diabetic nephropathy: a longitudinal study of urinary albumin excretion. Acta Endocrinol (Copenh) 100:550–555, 1982Google Scholar
  4. 4.
    Mogensen CE, Christensen CK, Predicting diabetic nephropathy in insulin-dependent patients. N Engl J Med 311:89–93, 1984Google Scholar
  5. 5.
    Mathiesen ER, Oxenbøll B, Johansen K, Svendsen PA, Deckert T, Incipient nephropathy in type 1 (insulin-dependent) diabetes. Diabetologia 26:406–410, 1984Google Scholar
  6. 6.
    Feldt-Rasmussen B, Mathiesen ER, Deckert T, Effect of two years of strict metabolic control on the progression of incipient nephropathy in insulin-dependent diabetes. Lancet II:1300–1304, 1986Google Scholar
  7. 7.
    Christensen CK, Mogensen CE, Effect of antihypertensive treatment on progression of incipient diabetic nephropathy. Hypertension 7 [Suppl II]:109–113, 1985Google Scholar
  8. 8.
    Zatz R, Dunn BR, Meyer TW, Anderson S, Rennke HG, Brenner BM, Troy JL, DeGraphenried RL, Noddin JL, Nunn AW, Sandstrom D, Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 77:1925–1930, 1986Google Scholar
  9. 9.
    Marre M, Chatellier G, Leblanc H, Guyenne T-T, Ménard J, Passa P, Prevention of diabetic nephropathy with enalapril in normotensive diabetics with microalbuminuria. BMJ 297:1092–1095, 1988Google Scholar
  10. 10.
    Mathiesen ER, Hommel E, Giese J, Parving H-H, Efficacy of captopril in postponing nephropathy in normotensive insulin dependent diabetic patients with microalbuminuria. BMJ 303:81–87, 1991Google Scholar
  11. 11.
    Melbourne Diabetic Nephropathy Study Group, Comparison between perindopril and nifedipine in hypertensive and normotensive diabetic patients with microalbuminuria. BMJ 302:210–216, 1991Google Scholar
  12. 12.
    Rudberg S, Aperia A, Freyschuss U, Persson B, Enalapril reduces microalbuminuria in young normotensive type 1 (insulin-dependent) diabetic patients irrespective of its hypotensive effect. Diabetologia 33:470–476, 1990Google Scholar
  13. 13.
    Hallab M, Billiard A, Lejeune JJ, Bled F, Girault A, Fressinaud P, Marre M, Dissociation des effets hypotenseurs et hémodynamiques rénaux d'un inhibiteur de l'enzyme conversion chez des diabètiques insulinodépendants avec néphropathie débutante. Arch Mal Coer 84:383–386, 1991Google Scholar
  14. 14.
    Wiegmann TB, Herron KG, Chonko AM, MacDougall ML, Moore WV, Effect of angiotensin-converting enzyme inhibition on renal function and albuminuria in normotensive type 1 diabetic patients. Diabetes 41:62–67, 1992Google Scholar
  15. 15.
    Viberti GC, Mogensen CE, Keen H, Jacobsen FK, Jarret RJ, Christensen CK, Urinary excretion of albumin in normal man: the effect of water loading. Scand J Clin Lab Invest 42:147–151, 1982Google Scholar
  16. 16.
    Christensen CK, Ørskov C, Rapid screening PEG radioimmunoassay for quantification of pathological microlbuminuria. Diabetic Nephropathy 3:92–94, 1984Google Scholar
  17. 17.
    Engbaek F, Christensen SE, Jespersen B, Enzyme immunoassay of hemoglobin A1c: analytical characteristics and clinical performance for patients with diabetes mellitus, with and without uremia. Clin Chem 35:93–97, 1989Google Scholar
  18. 18.
    Mau Pedersen M, Schmitz A, Pedersen EB, Danielsen H, Christiansen JS, Acute and long-term renal effects of angiotensin converting enzme inhibition in normotensive, normoalbuminuric insulin-dependent diabetic patients. Diabetic Med 5:562–569, 1988Google Scholar
  19. 19.
    Mau Pedersen M, Christensen SE, Christiansen JS, Pedersen EB, Mogensen CE, Ørskov H, Acute effects of a somatostatin analogue on kidney function in type 1 diabetic patients. Diabetic Med 7:304–309, 1990Google Scholar
  20. 20.
    Mogensen CE, Christensen CK, Blood pressure changes and renal function in incipient and overt diabetic nephropathy. Hypertension 7 [Suppl II]:64–73, 1985Google Scholar
  21. 21.
    Mogensen CE, Early glomerular hyperfiltration in insulin-dependent diabetics and late nephropathy. Scand J Clin Lab Invest 46:201–206, 1986Google Scholar
  22. 22.
    Rudberg S, Persson B, Dahlqvist G, Increased glomerular filtration rate predicts diabetic nephropathy: results from an 8 year prospective study. Kidney Int 41:822–828, 1992Google Scholar
  23. 23.
    Abu-Romeh SH, Nawaz MK, Ali JH, Al-Suhaili AR, Abu-Jayyab AK, Short-term effect of angiotensin-converting enzyme inhibitor enalapril in incipient diabetic nephropathy. Clin Nephrol 31:18–21, 1989Google Scholar
  24. 24.
    Jenkins DAS, Cowan P, Collier A, Watson ML, Clarke BF, Blood glucose control determines the renal haemodynamic response to angiotensin converting enzyme inhibition in type 1 diabetes. Diabetic Med 7:252–257, 1989Google Scholar
  25. 25.
    Drummond K, Levy-Marchal C, Laborde K, Kindermans C, Wright C, Dechaux M, Czernichow P, Enalapril does not alter renal function in normotensive, hyperfiltrating type 1 (insulin-dependent) diabetic children. Diabetologia 32:252–260, 1989Google Scholar
  26. 26.
    Vora J, Owens DR, Luzio S, Atica J, Ryder REJ, Williams S, Hayes TM, Glomerular function during angiotensin converting (ACE) inhibition in early insulin dependent diabetes (IDDs) (abstract). Diabetic Med 3:584 A, 1986Google Scholar
  27. 27.
    Mau Pedersen M, Christensen CK, Hansen KW, Christiansen JS, Mogensen CE, ACE-inhibition and renoprotection in early diabetic nephropathy: response to enalapril acutely and in long term combination with conventional antihypertensive treatment. Clin Invest Med 14:642–651, 1991Google Scholar
  28. 28.
    Mogensen CE, Hansen KW, Østerby R, Damsgaard EM, Blood pressure elevation versus abnormal albuminuria in the genesis and prediction of renal disease in diabetes. Diabetes Care 15:1192–1204, 1992Google Scholar
  29. 29.
    Raij L, Shultz PJ, Tolins JP, Possible mechanism for the renoprotective effect of angiotensin converting enzyme inhibitors. J Hypertens 7 [Suppl 7]:S33-S37, 1989Google Scholar

Copyright information

© Springer-Verlag 1993

Authors and Affiliations

  • K. W. Hansen
    • 1
  • M. Mau Pedersen
    • 1
  • J. S. Christiansen
    • 1
  • C. E. Mogensen
    • 1
  1. 1.Medical Department M (Diabetes and Endocrinology)Aarhus KommunehospitalAarhusDenmark

Personalised recommendations